Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 140 results found since Jan 2013.
Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research
TIMELESS promotes the proliferation and migration of lung adenocarcinoma cells by activating EGFR through AMPK and SPHK1 regulation
CONCLUSIONS: Our study revealed that siTIM could inhibited EGFR activation through activating AMPK and inhibiting SPHK1 expression, as well as influencing mitochondrial function and alter the ATP level; TIM's high expression in LUAD is an important factor and a potential key target in LUAD.PMID:37433364 | DOI:10.1016/j.ejphar.2023.175883
Source: European Journal of Pharmacology - July 11, 2023 Category: Drugs & Pharmacology Authors: Houqing Yin Zequn Wang Dan Wang Muhadaisi Nuer Mengyuan Han Peng Ren Shanwu Ma Chutong Lin Jingjing Chen Haocheng Xian Dongmei Ai Xuejun Li Shaohua Ma Zhiqiang Lin Yan Pan Source Type: research
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highligh...
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research
Study on co-delivery of pemetrexed disodium and Bcl-2 siRNA by poly- γ-glutamic acid-modified cationic liposomes for the inhibition of NSCLC
Drug Dev Ind Pharm. 2023 Feb 20:1-18. doi: 10.1080/03639045.2023.2182125. Online ahead of print.ABSTRACTDue to the complexity of pathophysiology of non-small cell lung cancer (NSCLC) and susceptibility of single chemotherapy to drug resistance, the combination of drugs and small interfering RNA (siRNA) may produce desired therapeutic effect on NSCLC through action of multiple pathways. We designed to develop poly-γ-glutamic acid-modified cationic liposomes (γ-PGA-CL) to co-deliver pemetrexed disodium (PMX) and siRNA to treat NSCLC. Firstly, γ-PGA was modified on surface of PMX and siRNA co-loaded cationic liposomes by e...
Source: Drug Development and Industrial Pharmacy - February 21, 2023 Category: Drugs & Pharmacology Authors: Huang Xiaoyu Song Ruonan Wang Xiao Kongfang He Rumeng Shan Xie Fei Guihua Huang Source Type: research
Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT
Eur J Pharm Sci. 2023 Jan 5:106372. doi: 10.1016/j.ejps.2023.106372. Online ahead of print.ABSTRACTEpidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKIs) was one of the main drugs in the treatment of non-small cell lung cancer (NSCLC). Previous studies had demonstrated that PDZ and LIM Domain 5 (PDLIM5) played an important role in EGFR TKIs resistance. However, there was no feasible method to eliminate EGFR TKIs resistance by suppressing this gene. Here, we formulated a novel mesoporous silica-loaded PDLIM5 siRNA (Small interfering RNA) nanoplatforms. The results have shown that PDLIM5 siRNA could be effect...
Source: European Journal of Pharmaceutical Sciences - January 9, 2023 Category: Drugs & Pharmacology Authors: Hao Wu Wen-Hao Lv Yang-Yang Zhu Ying-Ying Jia Fang Nie Source Type: research
Aspirin blocks AMPK/SIRT3-mediated glycolysis to inhibit NSCLC cell proliferation
Eur J Pharmacol. 2022 Aug 15:175208. doi: 10.1016/j.ejphar.2022.175208. Online ahead of print.ABSTRACTNon-small cell lung cancer (NSCLC) has the highest incidence and mortality in the world. Aspirin has been reported to promote apoptosis, inhibit proliferation, stemness, angiogenesis, cancer-associated inflammation and migration in NSCLC. But the effect of aspirin on aerobic glycolysis in NSCLC is less reported. In the present study, we investigated whether aspirin blocked aerobic glycolysis of NSCLC cell to inhibit proliferation. Our results showed that aspirin inhibited viability, PCNA expression, ability of colony forma...
Source: European Journal of Pharmacology - August 18, 2022 Category: Drugs & Pharmacology Authors: Guanghui Ren Yan Ma Xingjie Wang Zhaodi Zheng Guorong Li Source Type: research
